Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Import to Russia (June and Q1–Q2 2022)

Monday, July 25, 2022

In Q1–Q2 2022, Russia imported 397.8 billion rubles’ worth of ready-made pharmaceutical drugs (customs clearance and VAT included), up 8.7% from Q1–Q2 2021. As for bulk drugs, the import volume was 94.4 million rubles, up as much as 32.6% from Q1–Q2 2021. In physical terms, however, the growth rates were negative for both groups: –9.4% for ready-made drugs, with 803 million packages imported, and –32.7% for bulk drugs, with 731.4 million MDUs (minimum dosage units) imported.

The import of pharmaceutical drugs in June 2022 generally followed the trends of the first six months of 2022. The growth rate was 18% for the import of ready-made drugs, while the import of bulk drugs increased 2.9 times against June 2021, which can be explained by the so-called “low base” (back in June 2021, Russia imported 8.3 billion rubles’ worth of bulk drugs—nearly half the average in 2021). Yet, the results of June 2022 could actually be called outstanding, because Russia imported more than 24 billion rubles’ worth of bulk drugs, mostly expensive items.

Due to what is happening in the world right now, the structure of payments for imported drugs in January–June 2022 underwent significant changes. First, the share of imports of ready-made drugs paid in Russian rubles slightly decreased—from 94.3% in Q1–Q2 2021 to 92.5% in Q1–Q2 2022. Second, the number of payment currencies grew by four, including rather unusual for the Russian pharmaceutical market currencies, such as the Polish zloty and the Canadian dollar. Finally, the share of imports paid for in Chinese yuans increased more than 6 times against Q1–Q2 2021.

AstraZeneca had the best growth rates among the top 20 importers of ready-made drugs in June 2022—its imports went up 8.6 times in monetary terms against June 2021. The import of its anticancer drug Lynparza increased 28 times, which contributed to the company’s growth rates the most. AstraZeneca is followed by Astellas (imports grew 4.3 times); its antitumor agent, antiandrogenic drug Xtandi, helped the growth rates.

As for the top 20 importers of bulk drugs, Roche (imports grew 56 times) and MSD (21 times) had the highest growth rates, contributing to the overall result of the group. Roche had high growth rates thanks to the import of two anticancer drugs, Perjeta and Kadcyla, packaged by R-Pharm at Ortat in Russia. The import of Keytruda, also packaged by R-Pharm, contributed to the growth rates of MSD.

Growth rates of imports of pharmaceuticals to Russia (EEU countries excluded), free circulation prices, customs clearance and VAT included, RUB (2017–2021, Q1–Q2 2022)